Penile implant infection prevention: evidence, risk and questions to ask

Infection is one of the complications people consider when weighing penile implant surgery. It is not the same as a routine wound problem: bacteria can adhere to the device and form a biofilm, and an established implant infection may need antibiotics and further surgery, sometimes removal or exchange of the device. Many published series report low infection rates, but the estimates vary with the patients included, whether operations were primary or revision, the device and era, follow-up, and how infection was defined. No study can promise an individual outcome.

This article explains what published studies actually measured, why prevention strategies are biologically plausible, and where the evidence remains uncertain. It is educational material, not an individual assessment or antibiotic plan. A qualified urologist should discuss a person’s medical history, device options and local protocol.

How infection can start and why prevention matters

During implantation, bacteria can enter the operative field from skin or other sources. If organisms attach to an implant surface, they may produce a biofilm: a structured community embedded in a protective matrix. Biofilm can make organisms harder for host defences and antimicrobials to clear, and it can complicate culture-based diagnosis. This helps explain why a device infection can have consequences beyond temporary redness or a superficial wound issue. It does not mean every implant becomes colonised or that every suspected infection has the same cause.[10]

Infection prevention therefore has several distinct aims: reduce bacterial transfer into the field, reduce the chance that transferred organisms attach and persist, and recognise complications early enough for proper assessment. These are related but not interchangeable. A coating is intended to alter bacterial attachment or survival at the device surface; a sterile operative process aims to reduce contamination; and antibiotics are a clinician-directed part of peri-operative care. None removes all risk, and a result associated with one bundled approach cannot automatically be credited to one component.

The practical consequence is that a published infection percentage describes a defined group and observation period, not a personal probability. Infection may lead to additional assessment, antimicrobial treatment, implant removal or exchange, and a changed erectile-function plan while recovery and reconstruction are considered. Ask the surgeon how their team defines and follows an infection, what symptoms trigger contact, and who coordinates care if you are away from the operating centre.

Coatings and operative technique: plausible approaches, not guarantees

Implant coatings are designed to reduce bacterial adhesion or expose organisms at the device surface to antimicrobial agents. Commercial systems differ: some use antibiotic impregnation, while hydrophilic surfaces can absorb a solution chosen by the operating team. Laboratory rationale and observational clinical results support continued study, but coatings do not sterilise the patient or substitute for a careful operative process. The type of coating, the implant model, the accompanying preparation and the population all matter when comparing studies.

A single-surgeon historical series followed 2,347 inflatable penile prosthesis (IPP) operations from 2002 to 2011. It reported infection in 7 of 1,511 cases (0.46%) in the later period after an infection-retardant-coated device and a “no-touch” technique were both in use, compared with 14 of 704 (about 2.0%) in the earlier coated-device period and 7 of 132 (5.3%) with non-coated devices.[5] The time periods were sequential, not randomised; surgical practice and other factors could have changed alongside the interventions. The finding is consistent with benefit but cannot isolate the independent effect of coating or technique, nor serve as a guaranteed rate for another centre.

A separate umbrella review pooling prior reviews found an association between antibiotic-coated and non-coated implants (pooled odds ratio 0.47, 95% confidence interval 0.31–0.72), but heterogeneity was very high (I² 95%).[4] The review attempted to exclude source reviews that had already analysed the same cohorts; its pooled estimate nevertheless remains highly heterogeneous, and the included studies differ in definitions and eras. An odds ratio is not an absolute personal risk reduction; the pooled association does not prove the same benefit for every device or patient.

“No-touch” is a description of a contamination-minimising operative approach intended to limit contact between the implant and skin or other potentially contaminated surfaces. The reported series is encouraging, but because it combined the approach with coated devices and a later surgical era, it cannot establish that the method alone caused the observed difference. Questions about a team’s process are reasonable; this article does not provide a surgical technique guide.

The umbrella review also pooled two source reviews for “no-touch”: 12 infections among 2,144 patients (0.56%) in the combined-technique group versus 88 among 2,492 (3.53%) without the combined technique. Its estimate was not statistically significant (OR 0.29, 95% CI 0.04–2.16; I² 85%; p=0.23). The review limited included infection outcomes to onset within one year and excluded systematic reviews that reused cohorts already analysed in another included review.[4] This pooled, imprecise result does not confirm benefit or establish absence of benefit; it tempers the much lower rate in the sequential single-surgeon series above.

A separate systematic review of primary inflatable implants pooled 102,572 patients across 11 observational studies and reported a hazard ratio of 0.38 (95% CI 0.28–0.51) for coated versus non-coated devices, with I² 85.5%.[11] This supports an association in primary IPP data, but high heterogeneity and observational designs remain. It cannot answer whether the result applies to revision surgery or each patient subgroup.

Primary surgery, revision surgery and device type are different comparisons

Primary implantation means the first implant operation; revision means an operation on an existing implant, which may involve device exchange or another form of reoperation. Revision fields can include scar tissue, prior device exposure and a history of mechanical or infectious problems, so primary and revision groups should not be treated as interchangeable.

An umbrella review reported infections in 193 of 6,027 first operations (3.2%) and 179 of 1,977 revision operations (9.0%) across the studies it pooled. Its comparison gave an odds ratio of 0.36 for first surgery versus revision (95% CI 0.29–0.45; I² 20%).[4] That review restricted infection onset to no more than one year after implantation and excluded source reviews using cohorts already analysed in another included review. These are pooled study counts rather than a prediction for a particular operation. Differences in patient selection, reasons for revision, implant era and follow-up remain relevant.

A voluntary manufacturer post-market registry analysis followed reports associated with 36,391 primary inflatable implants submitted from 2000 to 2011. The endpoint was infection-related revision, not every diagnosed infection: the reported revision proportion was 4.6% among 7,031 non-coated devices and 1.4% among 29,360 hydrophilic-coated devices. Observation differed (up to 11 years for non-coated reports and 8 years for coated reports), so these proportions are not equal-duration comparisons and should not be read as a direct causal estimate.[6]

The same umbrella review reported a higher pooled infection proportion for malleable than inflatable devices in the included studies (197/2,596, 7.6%, versus 666/44,603, 1.5%; odds ratio 3.51, 95% CI 1.41–8.74; I² 96%).[4] Very high heterogeneity means the studies did not agree closely. Device choice is also linked to patient characteristics, surgical setting and study era; this comparison does not establish that one device type itself causes the difference or is the better choice for an individual. Compare like with like: primary with primary, revision with revision, and the same infection definition and follow-up window where possible.

For a discussion of the operation’s scope and what drives a quote, see the penile implant surgery cost in Turkey information for a malleable implant, or the separate inflatable penile implant prices in Turkey page for a three-piece inflatable device. These pages describe commercial information, not a clinical recommendation; the two device pathways should not be conflated.

Diabetes, HbA1c and antibiotics: what the studies do not settle

Diabetes is biologically relevant to wound healing and infection risk, but penile implant studies have not produced one consistent estimate or a universally accepted HbA1c threshold. A 2021 systematic review and meta-analysis included 41 studies; in its diabetes comparison, 9,041 men with diabetes and 36,517 without diabetes contributed data. The pooled odds ratio was 1.53 (95% CI 1.15–2.04).[3] The authors described limitations in the underlying literature, including retrospective designs, incomplete controls and varied reporting. This result indicates an association in pooled data; it cannot tell an individual whether an implant infection will occur.

An umbrella review found that the diabetes association was not statistically significant in its pooled analysis (OR 2.28, 95% CI 0.85–6.17; I² 96%; p=0.10). For higher versus lower HbA1c categories, its estimate was especially imprecise (OR 1.16, 95% CI 0.06–22.85; I² 96%).[4] Wide intervals and high heterogeneity mean that these results are compatible with a broad range of effects. The disagreement between reviews is a reason to discuss uncertainty, not to choose whichever estimate sounds most reassuring.

A multicentre prospective study used a prospectively built database of implant procedures performed in 2009–2015 at four private urology/andrology centres. Among 902 procedures, 685 (76%) were malleable and 217 (24%) inflatable; 80 infections were recorded (8.9%). The reported mean follow-up was 28.3 months (range 0.4–78.3). Infection rose across HbA1c categories, from 1.3% below 6.5% to 22.4% above 9.5%; the study-derived ROC threshold was 8.5% (sensitivity 80%, specificity 65%).[12] This is an observational association from a cohort dominated by malleable devices; the ROC cut-off does not prove that lowering HbA1c or postponing surgery will reduce infection, and it is not a universal threshold. A systematic review of six studies found inconsistent results: some reported higher mean HbA1c among infected patients, while others found no significant difference.[7] A 2026 review of studies where at least 70% of participants had diabetes included 10,024 people and reported an overall infection estimate of 4.3% (95% CI 3.9–4.8); mean follow-up was 37.2 months. It also reported a study-level comparison of 9.1% versus 3.8% for studies with average HbA1c at or above 8% versus lower study averages.[8] That comparison is not a patient-level threshold, and most included evidence was retrospective.

Antibiotic prophylaxis is a clinical decision, not a self-treatment recommendation. A multi-centre retrospective cohort of 804 diabetic patients undergoing primary implant surgery found postoperative device infection in 5.6% of the 391 patients given the study’s AUA-recommended regimen and 1.9% of the 413 given heterogeneous nonstandard regimens; the reported odds ratio was 2.8 (95% CI 1.1–7.3). Explantation was 8.3% versus 2.0% (OR 3.6, 95% CI 1.4–9.1).[9] Because treatment was not randomised and regimens were not one uniform alternative, this association cannot identify a superior regimen or justify copying an antibiotic combination. The authors called for prospective research. The AUA statement itself is a general urologic best-practice document; it does not make this observational comparison into an individual prescription.[2]

Planning a consultation and follow-up

Bring a complete medication and medical-history list, including diabetes management, prior implant procedures, previous device infection or wound problems, allergies and any relevant urinary or skin infection history. Ask the urologist to explain the patient-specific factors they consider, whether the proposed implant is malleable or inflatable, and whether the operation is primary or revision. These details determine which research comparisons are most relevant.

• Which published infection outcome best matches my situation: superficial wound infection, device infection, removal/explantation, or infection-related revision?
• For patients like me, what denominator and follow-up period support the centre’s stated rate? Does it include primary and revision procedures separately?
• What device coating or surface is planned, and what evidence supports it for this device and operation?
• How does the team reduce contamination and monitor for complications? Who should I contact after discharge, including outside normal hours?
• How are diabetes and HbA1c considered in my case, and what is known versus uncertain about any proposed threshold or timing?
• What would happen if infection is suspected, including where assessment, treatment and any further surgery would be arranged?
• What is included in the written quote and aftercare plan, and who provides each part?

When discussing an inflatable three-piece implant, you can review the inflatable penile implant package details and ask the provider to itemise the care, follow-up and any exclusions in writing. For a malleable implant, check the distinct malleable penile implant package information. A package description is not evidence that a clinical service or follow-up is included unless the written terms say so; clarify who is responsible for care and how enquiries are shared.

How to read an infection percentage

Before comparing numbers, check five items: (1) the population—diabetes-only, all-comers, or another selected group; (2) the operation—primary or revision, malleable or inflatable; (3) the outcome—any infection, infection-related revision, or explantation; (4) the denominator and observation window; and (5) study design and uncertainty. A low percentage with short follow-up is not directly comparable with a long registry, and a revision endpoint misses infections managed without revision.

Absolute rates depend on the baseline population. An odds ratio compares odds in two groups; it is not a percentage-point reduction. A confidence interval expresses statistical uncertainty around an estimate under the model and data used; a very wide interval means the data are compatible with substantially different effects. I² describes between-study inconsistency in a meta-analysis, not an individual’s risk. When I² is high, the pooled average may be less transportable to a particular centre.

Evidence has limits here. Studies are often retrospective, use different infection definitions, include different device generations, and may draw on overlapping cohorts. A sequence of care changes over time can make a later group appear better without proving which change mattered. Manufacturer registries can contribute long-term data but have their own reporting and follow-up constraints. Use these results to prepare specific questions, not to promise prevention.

Just Clinic Istanbul is an independent marketing and lead-generation platform, not a healthcare provider or medical-tourism intermediary. Enquiries may be shared with authorised healthcare partners with your consent. The platform does not provide a diagnosis or replace advice from a qualified clinician.

References

1. Burnett AL, Nehra A, Breau RH, et al. Erectile Dysfunction: AUA Guideline. The Journal of Urology. 2018;200(3):633–641. Published online 7 May 2018; issue September 2018. doi: 10.1016/j.juro.2018.05.004. PMID: 29746858.
2. Lightner DJ, Wymer K, Sanchez J, Kavoussi L. Best Practice Statement on Urologic Procedures and Antimicrobial Prophylaxis. The Journal of Urology. 2020;203(2):351–356. Published online 23 August 2019; issue February 2020. doi: 10.1097/JU.0000000000000509. PMID: 31441676.
3. Gon LM, de Campos CCC, Voris BRI, Passeri LA, Fregonesi A, Riccetto CLZ. A systematic review of penile prosthesis infection and meta-analysis of diabetes mellitus role. BMC Urology. 2021;21:35. Published 10 March 2021. doi: 10.1186/s12894-020-00730-2. PMID: 33691670; PMCID: PMC7945372.
4. Menshchikov K, Menshchikov M, Yurasov D, Artamonov A. Risk factors for penile prosthesis infection: An umbrella review and meta-analysis. Arab Journal of Urology. 2024;22(2):96–101. Published online 29 July 2023; 2024 issue. doi: 10.1080/2090598X.2023.2242204. PMID: 38481412; PMCID: PMC10929667.
5. Eid JF, Wilson SK, Cleves M, Salem EA. Coated implants and “No Touch” surgical technique decreases risk of infection in inflatable penile prosthesis implantation to 0.46%. Urology. 2012;79(6):1310–1315. Published online 21 April 2012; issue June 2012. doi: 10.1016/j.urology.2011.11.076. PMID: 22521187.
6. Serefoglu EC, Mandava SH, Gokce A, Chouhan JD, Wilson SK, Hellstrom WJG. Long-term revision rate due to infection in hydrophilic-coated inflatable penile prostheses: 11-year follow-up. The Journal of Sexual Medicine. 2012;9(8):2182–2186. Published online 3 July 2012; issue August 2012. doi: 10.1111/j.1743-6109.2012.02830.x. PMID: 22759917.
7. Dick BP, Yousif A, Raheem O, Hellstrom WJG. Does Lowering Hemoglobin A1c Reduce Penile Prosthesis Infection? A Systematic Review. Sexual Medicine Reviews. 2021;9(4):628–635. Published online 5 August 2020; issue October 2021. doi: 10.1016/j.sxmr.2020.06.004. PMID: 32768358.
8. Corona G, Capogrosso P, Lee WG, et al. Penile prosthesis infection and diabetes mellitus: a systematic review and meta-analysis. The Journal of Sexual Medicine. 2026;23(1):qdaf340. Published online 5 January 2026. doi: 10.1093/jsxmed/qdaf340. PMID: 41489200.
9. Rezaee ME, Towe M, Osman MM, et al. A Multicenter Investigation Examining American Urological Association Recommended Antibiotic Prophylaxis vs Nonstandard Prophylaxis in Preventing Device Infections in Penile Prosthesis Surgery in Diabetic Patients. The Journal of Urology. 2020;204(5):969–975. Published online 10 June 2020; issue November 2020. doi: 10.1097/JU.0000000000001158. PMID: 32519913.
10. Swanton AR, Munarriz RM, Gross MS. Updates in penile prosthesis infections. Asian Journal of Andrology. 2020;22(1):28–33. Published online 2019. doi: 10.4103/aja.aja_84_19. PMID: 31489848; PMCID: PMC6958973.
11. Marquardt Filho N, Da Ros LU, Da Ros JPU, Carvalhal GF, Da Ros CT, Carvajal A. Infection rates in primary inflatable penile prosthesis: a systematic review and meta-analysis of antibiotic-coated versus non-coated devices. International Journal of Impotence Research. First published 20 July 2026; volume, issue and pages not assigned on the publisher record accessed. doi: 10.1038/s41443-026-01314-8. PMID: 42477170.
12. Habous M, Tal R, Tealab A, et al. Defining a glycated haemoglobin (HbA1c) level that predicts increased risk of penile implant infection. BJU International. 2018;121(2):293–300. Published online 1 December 2017; issue February 2018. doi: 10.1111/bju.14076. PMID: 29124870; PMCID: PMC7478354.